Want to see ACOG full AI Analyst Report?
ACOG Stock Chart & Stats
$9.41
$0.68(8.61%)
At close: 4:00 PM EDT
$9.41
$0.68(8.61%)
Day’s Range― - ―
52-Week Range$4.50 - $10.14
Previous Close$8.58
Volume108.17K
Average Volume (3M)122.76K
Market Cap
$198.18M
Enterprise Value$115.77M
Total Cash (Recent Filing)$41.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Dec 01, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding21,777,868
10 Day Avg. Volume109,345
30 Day Avg. Volume122,758
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.84
Price to Sales (P/S)11.24
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue7.59
Enterprise Value/Gross Profit8.44
Enterprise Value/Ebitda-4.20
Forecast
1Y Price Target
$18.00Price Target Upside91.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$25.71M
Bulls Say, Bears Say
Bulls Say
Commercial Growth And AdoptionRapid sequential product revenue and bottle growth indicate expanding commercial adoption rather than dependence on a single initial launch period. Rising prescriber, customer, and facility activity can create a broader recurring revenue base as the company continues converting demand into durable utilization.
Strong Product Gross MarginA gross margin near 94% provides substantial contribution potential from each incremental product sale and supports investment in commercialization and evidence generation. If sustained as volume grows, these unit economics can help the company absorb fixed costs and improve its path toward operating profitability.
Debt-free Balance SheetThe absence of reported debt reduces solvency and mandatory interest-payment pressure while the improved equity base offers greater financial flexibility than in earlier periods. This provides a stronger platform for funding commercialization and development, although continued cash burn could still erode that cushion.
Bears Say
Persistent Cash Burn And LossesSubstantial operating losses and worsening negative cash flow show that the business is not yet self-funding despite revenue growth. Continued outflows increase reliance on external financing, creating dilution and execution risk if commercialization proceeds more slowly than planned or profitability is delayed.
Payer Access FrictionLimited formulary activation can constrain prescription conversion even when physician and patient demand is present, slowing the transition from commercial activity to reimbursed revenue. Prolonged payer friction may also require continued selling and education investment, delaying operating leverage and broader market penetration.
Dependence On Future EvidenceSome future payer persuasion and promotional value depend on clinical and real-world evidence that has not yet fully arrived. Delays, inconclusive results, or a longer publication cycle could postpone coverage expansion and limit the company’s ability to convert current commercial traction into sustained growth.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $4.50 and its highest was $10.14 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $198.18M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Dec 01, 2026 which is in 56 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Aug 13, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.392 by -$0.008.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.34.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,777,868 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.392. Following the earnings report the stock price went up 2.433%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Cognition Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (91.29% Upside)
$18.00 (91.29% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum for ZUNVEYL: rapid sequential revenue growth (71% QoQ), healthy gross margins (~94%), improving net loss, robust organic demand (37% bottle growth) and encouraging prescriber/facility repeat metrics. Management is deliberately investing to scale commercial capabilities and evidence generation (BEACON positive; CONVERGE topline expected Q3). Key challenges are slower-than-expected payer/formulary activation, limited contracted coverage (~16%), and dependence on upcoming data and policy-driven plan behavior; the company remains unprofitable but projects operating profitability in 2027. On balance, the positive commercial execution and financial improvements outweigh the access and timing headwinds, with upside from future payer conversions.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$18.00
▲(91.29% Upside)
Technical Analysis
Anavex Life Sciences
―
AC Immune SA
―
Alector
―
Acumen Pharmaceuticals
―
Cognition Therapeutics
―
Ownership Overview
19.57% Insiders
0.06% Mutual Funds
46.34% Other Institutional Investors
34.00% Public Companies and
Individual Investors